

Questions (please circle answer):

- 1. Preclinical studies indicate that trastuzumab is synergistic with:**
 - a. Paclitaxel
 - b. 5-FU
 - c. Docetaxel
 - d. a and c
 - e. All of the above

- 2. The platinum salts damage DNA. Trastuzumab is synergistic with the platinum salts since it causes a transient increase in DNA repair.**
 - a. True
 - b. False

- 3. Which of the following is likely to be most synergistic with trastuzumab?**
 - a. Tamoxifen
 - b. Megestrol acetate
 - c. Fulvestrant
 - d. All of the above

- 4. Cardiotoxicity was the dose-limiting toxicity encountered in the phase I trastuzumab trials.**
 - a. True
 - b. False

- 5. BCIRG 101 and 102 assessed the efficacy of carboplatin or cisplatin in combination with docetaxel/trastuzumab.**
 - a. True
 - b. False

- 6. In the pivotal phase III trastuzumab trial, which regimen had the highest response rate?**
 - a. Paclitaxel/trastuzumab
 - b. Anthracycline/cyclophosphamide/trastuzumab
 - c. Trastuzumab alone
 - d. Capecitabine/trastuzumab
 - e. Cisplatin/trastuzumab

- 7. In the pivotal phase III trastuzumab trial, which regimen had the highest incidence of cardiotoxicity?**
 - a. Paclitaxel/trastuzumab
 - b. Anthracycline/cyclophosphamide/trastuzumab
 - c. Trastuzumab alone
 - d. Capecitabine/trastuzumab
 - e. Cisplatin/trastuzumab

Questions (please circle answer):

- 8. Several ongoing adjuvant trials are evaluating trastuzumab-containing regimens. Which of the following trials is/are evaluating carboplatin in combination with docetaxel/trastuzumab?**
- a. Intergroup N9831
 - b. NSABP B-31
 - c. BCIRG-006
 - d. a and c
 - e. All of the above
- 9. Which of the following statements is/are correct about the methodologies for assessing HER2 status?**
- a. False-negative results with IHC may be the result of formalin cross-linking the HER2 protein.
 - b. The concordance among pathologists is high with the Dako HercepTest™.
 - c. According to the BCIRG, FISH is a very reproducible test.
 - d. a and c
 - e. All of the above
- 10. Clinical trials have determined the optimal duration of trastuzumab therapy to be one month after progressing on the first trastuzumab-containing regimen.**
- a. True
 - b. False

To obtain a certificate of completion and receive credit for this activity, you must complete the exam, fill out the evaluation form and mail or fax both to: Postgraduate Institute for Medicine, P. O. Box 260620, Littleton, CO 80163-0620, FAX (303) 790-4876.

Evaluation Form

02-1125-ES-12

BCU8 | 2002

Conversations with Oncology Leaders

Bridging the Gap between Research and Patient Care

Postgraduate Institute for Medicine (PIM) respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. Please note, a certificate of completion is issued only upon receipt of your completed evaluation form.

Please answer the following questions by circling the appropriate rating:

5 = Outstanding 4 = Good 3 = Satisfactory 2 = Fair 1 = Poor

Extent to which program activities met the identified objectives

Upon completion of this activity, participants should be able to:

- More effectively utilize chemotherapy/trastuzumab combinations in appropriate patients with HER2-positive metastatic breast cancer. 5 4 3 2 1
- More effectively discern the risk of cardiotoxicity associated with various trastuzumab-containing regimens and apply this knowledge when choosing chemotherapeutic agents to minimize the potential for cardiotoxicity in your patients. 5 4 3 2 1
- Develop a more effective algorithm to assess HER2 status and utilize this in selecting appropriate candidates for trastuzumab therapy. 5 4 3 2 1

Overall effectiveness of the activity

- Objectives were related to overall purpose/goal(s) of activity 5 4 3 2 1
- Related to my practice needs 5 4 3 2 1
- Will influence how I practice 5 4 3 2 1
- Will help me improve patient care 5 4 3 2 1
- Stimulated my intellectual curiosity 5 4 3 2 1
- Overall quality of material 5 4 3 2 1
- Overall, the activity met my expectations 5 4 3 2 1
- Avoided commercial bias or influence 5 4 3 2 1

Will the information presented cause you to make any changes in your practice? ___Yes ___No
 If Yes, please describe any change(s) you plan to make in your practice as a result of this activity.

What other topics would you like to see addressed in future educational programs?

Degree: MD DO PharmD RN NP PA BS Other _____

I certify my actual time spent to complete this educational activity to be ___ hour(s).

Signature: _____

Please Print Clearly

Name: _____

Specialty: _____

Street Address: _____ Box/Suite: _____

City: _____ State: _____ Zip Code: _____

Phone Number: _____ Fax Number: _____ E-mail: _____

Breast Cancer™

U P D A T E

Editor

Neil Love, MD

Associate Editors

Michelle Finkelstein Paley, MD

Richard Kaderman, PhD

Writers

Lilliam Sklaver Poltorack, PharmD

Jennifer Motley, MD

Sally Bogert, RNC, WHCNP

Douglas Paley

Art Director

Albert Rosado

Web Design

John Ribeiro

Copy Editor

Pat Morrissey/Havlin

Audio Production

Frank Cesarano

Technical Services

Arly Ledezma

Production Coordinator

Cheryl Dominguez

Editorial Assistants

Patricia McWhorter

April Marcus

Tere Sosa

Contact Information

Neil Love, MD

Director, Physician and
Community Education

NL Communications, Inc.

University of Miami

Conference Center

400 SE Second Avenue

Suite 401

Miami, Florida 33131-2117

Fax: (305) 377-9998

E-mail:

nlove@med.miami.edu

Copyright © 2002 NL Communications, Inc. All rights reserved.

This program was supported by educational grants from AstraZeneca Pharmaceuticals, LP; Genentech, Inc.; and Roche Laboratories, Inc.

The audio tapes, compact discs, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.